Literature DB >> 11466617

NF-kappa B activation results in rapid inactivation of JNK in TNF alpha-treated Ewing sarcoma cells: a mechanism for the anti-apoptotic effect of NF-kappa B.

D Javelaud1, F Besançon.   

Abstract

We recently reported that inhibition of NF-kappa B activation as a consequence of the overexpression of a degradation-resistant form of I kappa B alpha [I kappa B alpha(A32/36)] sensitized Ewing sarcoma cells to TNF alpha-induced killing. The c-Jun N-terminal kinases (JNK) have been shown to participate in death signaling triggered by certain stimuli and are activated by TNF alpha. To obtain insight into the mechanism of the anti-apoptotic effect of NF-kappa B, we compared the profiles of JNK activation by TNF alpha in control cells and in cells in which NF-kappa B activation was impaired. We show here that JNK activation was transient in control cells but remained elevated in I kappa B alpha(A32/36)-expressing cells. NF-kappa B repressed specifically the JNK pathway, since the kinetics of activation of the other TNF alpha-activated-MAP kinase p38 were identical in both cells. Prolongation of JNK activation in I kappa B alpha(A32/36)-expressing cells was not inhibited by the broad spectrum caspase inhibitor Z-VAD-FMK and thus was not the consequence of caspase activation. Pretreatment of control cells with the phosphatase inhibitor vanadate greatly prolonged JNK activation by TNF alpha and resulted in induction of apoptosis by this cytokine. Moreover, overexpression of a dominant-negative mutant of JNK1 decreased TNF alpha-induced apoptosis in cells expressing the super repressor of NF-kappa B, indicating that the sustained activation of JNK1 participated in death signaling triggered by TNF alpha. Our results provide evidence that the repression of JNK activation by NF-kappa B participates in the anti-apoptotic effect of this transcription factor in TNF alpha-treated Ewing sarcoma cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11466617     DOI: 10.1038/sj.onc.1204570

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  32 in total

1.  Tuning of protein kinase circuitry by p38α is vital for epithelial tissue homeostasis.

Authors:  Celia Caballero-Franco; Min-Kyung Choo; Yasuyo Sano; Patcharee Ritprajak; Hiroaki Sakurai; Kinya Otsu; Atsushi Mizoguchi; Jin Mo Park
Journal:  J Biol Chem       Date:  2013-07-08       Impact factor: 5.157

2.  The p65/RelA subunit of NF-kappaB suppresses the sustained, antiapoptotic activity of Jun kinase induced by tumor necrosis factor.

Authors:  Julie Y Reuther-Madrid; David Kashatus; Shaoqiong Chen; Xiong Li; John Westwick; Roger J Davis; H Shelton Earp; Cun-Yu Wang; Albert S Baldwin
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

3.  Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice.

Authors:  Aditya Murthy; Virginie Defamie; David S Smookler; Marco A Di Grappa; Keisuke Horiuchi; Massimo Federici; Maria Sibilia; Carl P Blobel; Rama Khokha
Journal:  J Clin Invest       Date:  2010-07-12       Impact factor: 14.808

4.  RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma.

Authors:  Shilpi Arora; Irma M Gonzales; R Tanner Hagelstrom; Christian Beaudry; Ashish Choudhary; Chao Sima; Raoul Tibes; Spyro Mousses; David O Azorsa
Journal:  Mol Cancer       Date:  2010-08-18       Impact factor: 27.401

5.  NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity.

Authors:  Shuichi Fujioka; Jiangong Niu; Christian Schmidt; Guido M Sclabas; Bailu Peng; Tadashi Uwagawa; Zhongkui Li; Douglas B Evans; James L Abbruzzese; Paul J Chiao
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

6.  NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death.

Authors:  Sachiko Sakon; Xin Xue; Mutsuhiro Takekawa; Tomonari Sasazuki; Tatsuma Okazaki; Yuko Kojima; Jian-Hu Piao; Hideo Yagita; Ko Okumura; Takahiro Doi; Hiroyasu Nakano
Journal:  EMBO J       Date:  2003-08-01       Impact factor: 11.598

7.  Targeted therapies for bone sarcomas.

Authors:  Dominique Heymann; Françoise Rédini
Journal:  Bonekey Rep       Date:  2013-07-17

Review 8.  Immune cell-mediated liver injury.

Authors:  Nadia Corazza; Anastasia Badmann; Christoph Lauer
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

9.  Preclinical studies of celastrol and acetyl isogambogic acid in melanoma.

Authors:  Sabiha Abbas; Anindita Bhoumik; Russell Dahl; Stefan Vasile; Stan Krajewski; Nicholas D P Cosford; Ze'ev A Ronai
Journal:  Clin Cancer Res       Date:  2007-11-15       Impact factor: 12.531

Review 10.  NF-kappa B-mediated adaptive resistance to ionizing radiation.

Authors:  Kazi Mokim Ahmed; Jian Jian Li
Journal:  Free Radic Biol Med       Date:  2007-10-10       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.